Ratings BeiGene, Ltd.

Equities

BGNE

US07725L1026

Real-time Estimate Cboe BZX Other stock markets 03:55:11 2024-04-23 pm EDT			5-day change	1st Jan Change
138.9 ^USD	+6.04%		+3.39%	-23.16%

07:52pm	Sector Update: Health Care Stocks Rise in Afternoon Trading	MT
05:20pm	BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The company is in a robust financial situation considering its net cash and margin position.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
With an enterprise value anticipated at 3.96 times the sales for the current fiscal year, the company turns out to be overvalued.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Over the past four months, analysts' average price target has been revised downwards significantly.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
BEIGENE, LTD.	-23.01%	13.68B	B
VERTEX PHARMACEUTICALS INCORPORATED	-0.24%	103B	B+
REGENERON PHARMACEUTICALS, INC.	+3.44%	96.73B	B+
ARGENX SE	+1.66%	21.31B	B
BIONTECH SE	-16.21%	21.21B	B+
GENMAB A/S	-6.82%	18.79B	A-
WUXI APPTEC CO., LTD.	-41.41%	16.37B	A-
NEUROCRINE BIOSCIENCES, INC.	+6.66%	13.44B	C+
SAREPTA THERAPEUTICS, INC.	+22.24%	10.98B	C+
LEGEND BIOTECH CORPORATION	-22.20%	8.56B	D

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes